))
ADALTA LIMITED (1AD) - Revolutionizing Biotechnology: CEO Tim Oldham on i-body Platform and Breakthroughs in Fibrotic Disease Therapeutics
Manage episode 432531957 series 3570035
内容由Andrew Musgrave提供。所有播客内容（包括剧集、图形和播客描述）均由 Andrew Musgrave 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
What if you could harness the secrets of the shark immune system to combat diseases that have stumped traditional medicine? On this episode of ASX Briefs, we sit down with Tim Oldham, CEO of AdAlta Limited, to uncover how his team is revolutionizing biotechnology with their pioneering i-Body platform. From the depths of shark biology to cutting-edge drug discovery, Tim unfolds the extraordinary journey of creating ultra-small, highly specific protein therapeutics aimed at tackling fibrotic diseases.
Join us as Tim dives into the progress of AD-214, AdAlta’s promising candidate currently in clinical trials for idiopathic pulmonary fibrosis (IPF). With half a million people affected worldwide and no therapies to halt fibrosis progression, AD-214 offers genuine hope. We also explore the strategic directions of AdAlta's subsidiaries, AdSolis and Adcella, and how they’re pushing the boundaries of therapeutic development. Whether you’re a biotech enthusiast or just curious about ground-breaking medical innovations, this conversation is packed with insights you won’t want to miss.
73集单集
分享
